Metamizole use during first trimester—A prospective observational cohort study on pregnancy outcome
- 3 August 2017
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 26 (10) , 1197-1204
Abstract
Introduction: The analgesic metamizole (dipyrone) is not recommended during pregnancy due to limited experience. In several countries, metamizole has no market authorization because of agranulocytosis as a rare but severe adverse effect. However, in others, metamizole is available and widely used as a pain reliever, and its use occurs also during pregnancy, often followed by fears of potential teratogenic risk.Methods: This prospective observational cohort study compared pregnancy outcomes of 446 women exposed with metamizole in the first trimester with a randomly selected control cohort comprising 887 women not exposed to metamizole. Relevant data were obtained via structured questionnaires applied during the first trimester and 2 months after the expected date of birth between January 2000 and December 2015.Results: The rate of major birth defects (7/373, 1.9%) was not increased in the metamizole cohort (OR adjusted 1.15, 95% CI 0.4‐3.5). The cumulative incidences for spontaneous abortions did not reveal a significant difference between the exposed (12.2%, 32/446) and comparison cohort (19.4%, 77/887) (HR adjusted 0.72, 95% CI 0.5‐1.1). Elective terminations of pregnancy (ETOP), mostly for “social” reasons, were more frequent in the metamizole (12.5%, 45/446) than in the comparison cohort (9.4%, 50/887; HR adjusted 1.48, 95% CI 0.98‐2.2).Conclusions: Metamizole exposure in the first trimester does not seem to bear a substantial teratogenic risk. Our study results support reassurance in those instances where metamizole has been used during an unrecognized pregnancy or where its use appears indispensable.Keywords
Funding Information
- Federal Institute for Drugs and Medical Devices (BfArM, Germany)
This publication has 23 references indexed in Scilit:
- Kurzmitteilung zu den Perzentilwerten für die Körpermaße der NeugeborenenZeitschrift für Geburtshilfe und Neonatologie, 2010
- Statistical methods for estimating the probability of spontaneous abortion in observational studies—Analyzing pregnancies exposed to coumarin derivativesReproductive Toxicology, 2008
- Using observational cohort data for studying drug effects on pregnancy outcome—Methodological considerationsReproductive Toxicology, 2008
- A Population-Based Case-Control Teratologic Study of Oral Dipyrone Treatment during PregnancyDrug Safety, 2007
- Effects Of Maternally Administered Drugs On The Fetal And Neonatal KidneyDrug Safety, 2006
- Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylateUltrasound in Obstetrics & Gynecology, 2005
- Metamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2005
- Propensity Score Estimation With Boosted Regression for Evaluating Causal Effects in Observational Studies.Psychological Methods, 2004
- Use of Dipyrone during Pregnancy and Risk of Wilmsʼ TumorEpidemiology, 1996
- Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: A randomized studyAmerican Journal of Obstetrics and Gynecology, 1995